Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Kymera Therapeutics, Inc.NASDAQ: KYMR
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 55.4% from a year ago
Total equity stood at $1.51B at the end of Q2 FY2026, up 55.4% from a year earlier and down 2.0% from the prior quarter. Over 3 fiscal years it compounded at +47.7% a year.
Context
- Total equity amounted to 91.7% of total assets at the end of Q2 FY2026, up 5.8 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +55.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 1.58B USD
- Year-over-year change
- +89.0%
- 4-year CAGR
- +36.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.58B | +89.0% |
| FY2024 | 2024-12-31 | 835.62M | +111.6% |
| FY2023 | 2023-12-31 | 394.97M | -19.4% |
| FY2022 | 2022-12-31 | 490.15M | +6.6% |
| FY2021 | 2021-12-31 | 459.64M | — |
Total Equity vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's Jun 2026 total equity of $1.51B is the highest of the 5 companies compared; the peer median is $454.36M.
- Its year-over-year change of +55.4% is the 3rd highest of 5, against a peer median of +54.9%.
- Total equity amounts to 91.7% of total assets for KYMR, versus a peer median of 71.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.51B | +55.4% | +47.7% | 91.7% | |
| Aug 2026 | $968.31M | +160.1% | +21.1% | 81.0% | |
| Mar 2026 | $521.92M | +89.7% | -5.0% | 70.9% | |
| Mar 2026 | $386.8M | -41.4% | -8.4% | 59.7% | |
| Mar 2026 | $234.25M | +20.0% | -3.9% | 71.2% | |
| Peer median (excluding KYMR) | $454.36M | +54.9% | -4.4% | 71.1% | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 47.98M | 68.4M | 109.97M | 120.26M | 357.01M |
| Short-term Investments | 394.44M | 338.77M | 264.92M | 368.49M | 491.27M |
| Net Receivables | 135K | 2.54M | 18.76M | 947K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 9.71M | 11.67M | 20.58M | 22.94M |
| Total Current Assets | 451.27M | 419.42M | 405.32M | 510.27M | 871.21M |
| Property, Plant & Equipment (Net) | 21.31M | 22.24M | 101.08M | 97.86M | 85.53M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 125.19M | 152.33M | 61.43M | 362.16M | 776.96M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 8.14M | 9.15M | 7.93M | 7.74M | 9.11M |
| Total Non-current Assets | 154.63M | 183.72M | 170.44M | 467.77M | 871.6M |
| Total Assets | 605.91M | 603.13M | 575.76M | 978.04M | 1.74B |
| Account Payables | 4.01M | 4.34M | 7.08M | 5.99M | 4.01M |
| Short-term Debt | 0 | 0 | 0 | 0 | 13.76M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 61.74M | 35.26M | 37.88M | 13.58M | 22.93M |
| Other Current Liabilities | 228K | 303K | 23.16M | 223K | 24.21M |
| Total Current Liabilities | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 39.3M | 28M | 16.77M | 0 | 11.44M |
| Other Non-current Liabilities | 66K | 248K | 0 | 0 | 0 |
| Total Non-current Liabilities | 53.73M | 41.64M | 95.1M | 74.65M | 79.94M |
| Total Liabilities | 146.27M | 112.98M | 180.79M | 142.42M | 163.15M |
| Common Stock | 5K | 6K | 6K | 7K | 8K |
| Retained Earnings | (228.98M) | (383.79M) | (530.75M) | (754.61M) | (1.07B) |
| Accumulated OCI | (660K) | (4.95M) | (552K) | (1.49M) | 1.8M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 459.64M | 490.15M | 394.97M | 835.62M | 1.58B |
| Total Debt | 17.96M | 17.34M | 84.67M | 87.76M | 82.25M |
| Net Debt | (30.01M) | (51.06M) | (25.29M) | (32.5M) | (274.76M) |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.